Effect of an Intervention to Prevent Acute Kidney Injury Versus Standard Care in High-risk Patients After Major Surgery
Launched by UNIVERSITY HOSPITAL MUENSTER · Mar 1, 2022
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new approach to prevent a condition called acute kidney injury (AKI) in patients who are at higher risk after undergoing major surgery. AKI can happen when the kidneys don't work well after surgery, leading to serious health issues. The researchers want to see if using a specific set of supportive care measures—called the KDIGO bundle—can help reduce the chances of AKI in these patients. Participants will be divided into groups based on certain markers in their blood, known as CCL14, to see how effective the approach is for different individuals.
To be eligible for this trial, patients must be adults aged 18 and older who have experienced moderate to severe AKI within 72 hours after surgery. However, those who are on dialysis, have had a kidney transplant, or have certain medical conditions like HIV or hepatitis will not be included. Participants in the study can expect to receive either the new supportive care bundle or standard care, and they will be monitored to see how their kidneys respond. This trial aims to find better ways to care for patients at risk of kidney problems after surgery, ultimately improving their recovery and health outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adult patients (age ≥18 years)
- • 2. Moderate or severe AKI ((defined by the 2012 KDIGO criteria, KDIGO stage 2 and 3), determined by either serum creatinine or urine output) within 72h after a surgical procedure
- • 3. Written informed consent
- Exclusion Criteria:
- • 1. Dialysis-dependent chronic kidney disease
- • 2. Prior kidney transplant
- • 3. Infections with human immunodeficiency virus or hepatitis
- • 4. Hepatorenal syndrome
- • 5. Pregnancy or breast-feeding
- • 6. Participation in another interventional trial that investigates a drug that affects the kidney function within the last 3 months
- • 7. Persons held in an institution by legal or official order
- • 8. Persons with any kind of dependency on the investigator or employed by the responsible institution or investigator
About University Hospital Muenster
University Hospital Münster is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the institution leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous investigations aimed at improving patient outcomes and developing new therapeutic strategies. With a strong focus on collaboration and ethical research practices, University Hospital Münster plays a pivotal role in translating scientific discoveries into practical applications, fostering a culture of inquiry that benefits both the medical community and the patients it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Münster, , Germany
Patients applied
Trial Officials
Zarbock, MD
Study Chair
University Hospital Muenster, Dept. of Anesthesiology, Intensive Care Therapy and Pain Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials